Older corneas "just as good" for transplant

Article

Corneas from donors up to the age of 75 are suitable for transplantation, according to a study published in the April 2008 issue of Ophthalmology.

Corneas from donors up to the age of 75 are suitable for transplantation, according to a study published in the April 2008 issue of Ophthalmology.

Edward Holland, MD of the University of Rochester Medical Center, US and colleagues on the Cornea Donor Study conducted the multicentre prospective, double-masked, controlled five-year trial of 1090 subjects to establish a comparison between graft survival in tissue from donors under the age of 65 with tissue taken from older donors.

Probability of graft failure, defined as three months’ consecutive impact on vision due to corneal opacity or regraft requirement, was 14% across both donor age groups (<66 years and ≥66 years). There was no statistically significant correlation between donor age and graft failure or survival, nor was there a statistically significant difference between age groups over the causes of graft failure.

Thus the researchers concluded that donor age is not a significant variable in graft failure. Dr Holland estimates that this will increase the pool of available donor corneas by 25–30%.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.